Similar articles

• Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis.

  Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS; AIPRD Study Group. Jafar TH, et al. Ann Intern Med. 2003 Aug 19;139(4):244-52. doi: 10.7326/0003-4819-139-4-200308190-00006. Ann Intern Med. 2003. PMID: 12965979
• Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: proteinuria and blood pressure levels?

  Mulrow CD, Townsend RR. Mulrow CD, et al. Ann Intern Med. 2003 Aug 19;139(4):296-8. doi: 10.7326/0003-4819-139-4-200308190-00013. Ann Intern Med. 2003. PMID: 12965986 No abstract available.
• Summaries for patients. Using a type of blood pressure medicine, angiotensin-converting enzyme inhibitors, to prevent worsening of kidney disease unrelated to diabetes.

  ACE Inhibition in Progressive Renal Disease Study Group. ACE Inhibition in Progressive Renal Disease Study Group. Ann Intern Med. 2001 Jul 17;135(2):S-21. doi: 10.7326/0003-4819-135-2-200107170-00003. Ann Intern Med. 2001. PMID: 11463005 No abstract available.
• Preventing renal disease progression: is it the drug or the blood pressure reduction, or both?

  Weir MR. Weir MR. Curr Hypertens Rep. 2000 Dec;2(6):497-9. doi: 10.1007/s11906-996-0030-y. Curr Hypertens Rep. 2000. PMID: 11062593 Review. No abstract available.
• Evolution of drugs that preserve renal function.

  Basta E, Bakris GL. Basta E, et al. J Clin Pharmacol. 2000 Sep;40(9):978-89. doi: 10.1177/00912700022009701. J Clin Pharmacol. 2000. PMID: 10975069 Review.